Patents Assigned to ZymoGenetics
  • TML polynucleotides
    Publication number: 20080194484
    Abstract: The present invention is directed to polynucleotides, peptides, variants, and uses thereof for a novel peptide fragment designated TML peptides. Binding of the peptide fragment has been shown in kidney and small intestine. The present invention further includes agonists, antagonists, variants, antibodies, host cells expressing the cDNA encoding the novel TML peptides and methods for increasing gastric motility and secretion of digestive proteins and hormones using the novel TML peptides.
    Type: Application
    Filed: January 16, 2008
    Publication date: August 14, 2008
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Stephen R. Jaspers, Paul D. Bishop
  • Polynucleotides encoding cytokine receptor zalpha11
    Patent number: 7411056
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: November 18, 2003
    Date of Patent: August 12, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • IL-21 antagonists
    Patent number: 7410780
    Abstract: The polypeptides, and the polynucleotides encoding for them, described herein are IL-21 antagonists that bind with specificity and exhibit an EC50 that is not detectable in receptor binding studies. These molecules have mutations in the D helix of the IL-21 molecule, and can be used to inhibit the activity of IL-21 with its cognate receptor.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: August 12, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, James W. West, Julia E. Novak
  • Thrombin compositions
    Patent number: 7393674
    Abstract: Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 mM CaCl2, 0.03% to 1% (w/v) of a surfactant or high-molecular-weight polyethylene glycol, and a physiologically acceptable buffer, or may be in lyophilized form.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: July 1, 2008
    Assignee: Zymogenetics, Inc.
    Inventors: Shan Jiang, Richard I. Senderoff, Jeffrey D. Meyer
  • Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies
    Patent number: 7393684
    Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: July 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
  • Soluble interleukin-20 receptor
    Patent number: 7387780
    Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: June 17, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Wenfeng Xu, Karen L. Madden, James D. Kelly, Cindy A. Sprecher, Cameron S. Brandt, Mark W. Rixon, Scott R. Presnell, Brian A. Fox
  • Growth factor homolog zvegf3 polynucleotides
    Patent number: 7387885
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: June 17, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker, Debra G. Gilbertson, James W. West
  • Dimeric fusion proteins and materials and methods for producing them
    Patent number: 7381794
    Abstract: Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: June 3, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Margaret D. Moore, Brian A. Fox
  • Growth factor homolog zvegf4
    Patent number: 7375182
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: May 20, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
  • Method for treating inflammation
    Patent number: 7364732
    Abstract: A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny Thompson, Hal Blumberg, Yasmin A. Chandrasekher
  • TML polynucleotides
    Patent number: 7354739
    Abstract: The present invention is directed to polynucleotides, peptides, variants, and uses thereof for a novel peptide fragment designated TML peptides. Binding of the peptide fragment has been shown in kidney and small intestine. The present invention further includes agonists, antagonists, variants, antibodies, host cells expressing the cDNA encoding the novel TML peptides and methods for increasing gastric motility and secretion of digestive proteins and hormones using the novel TML peptides.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: April 8, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher, Stephen R. Jaspers, Paul D. Bishop
  • Mouse cytokine receptor Zcytor16
    Patent number: 7351555
    Abstract: Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as “mouse Zcytor16,” which can bind and antagonize the IL-TIF cytokine.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
    Patent number: 7351689
    Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: April 1, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
  • Growth factor homolog ZVEGF4
    Patent number: 7323446
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: January 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Teresa Gilbert, Charles E. Hart, Paul O. Sheppard, Debra G. Gilbertson
  • Use of interleukin-24 to treat ovarian cancer
    Patent number: 7323164
    Abstract: The present invention relates to the anti-cancer activity of IL-24 polypeptide molecules. IL-24 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-24 for decreasing proliferation of ovarian cancer cells, treating ovarian cancer, amongst other uses disclosed. IL-24 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: January 29, 2008
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-IG FUSION MOLECULE
    Publication number: 20070274984
    Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
    Type: Application
    Filed: May 15, 2007
    Publication date: November 29, 2007
    Applicants: ARES TRADING S.A., ZYMOGENETICS, INC.
    Inventors: Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
  • Beta-defensins
    Patent number: 7294613
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zamp1, a novel member of the ?-defensin family. The polypeptides, and polynucleotides encoding them, exhibit anti-microbial activity and may be used in the study or treatment of microbial infections. The present invention also includes antibodies to the zamp1 polypeptides.
    Type: Grant
    Filed: March 5, 2002
    Date of Patent: November 13, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: David A. Adler, James L. Holloway, Nand Baindur, Stephanie Beigel-Orme, Paul O. Sheppard
  • Uses of human Zven proteins and polynucleotides
    Patent number: 7291589
    Abstract: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: November 6, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Penny J. Thompson, Katherine E. Lewis, Richard M. Garcia
  • Methods of treating autoimmune diseases using IL-21
    Patent number: 7276478
    Abstract: Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical compositions can include IL-21 polypeptides and active fragments thereof.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: October 2, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Andrew J. Nelson
  • secretory signal
    Patent number: 7271255
    Abstract: Novel Pichia methanolica secretory signal polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods of using are disclosed. Methods of producing large amounts of recombinant proteins by employing DNA constructs having a polypeptide of interest preceded by a novel Pichia methanolica secretory signal sequence.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: September 18, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Christopher K. Raymond, Michael R. Stamm